Dr. Brufsky on CDK 4/6 Inihibitors in Neoadjuvant Breast Cancer Treatment
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.
In the neoadjuvant setting, using CDK 4/6 inhibitors with hormonal therapy is in the future of breast cancer treatment, particularly with luminal A tumors.
Response trials are currently ongoing that may guide in the decision to use CDK 4/6 inhibitors in this setting.
